Results 21 to 30 of about 616,871 (170)

Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy. [PDF]

Cancers (Basel)
Advances in the molecular characterization of acute myeloid leukemia (AML) in recent decades have driven the development and clinical introduction of several targeted therapies, and menin inhibitors are the most recent additions to the therapeutic ...
Zhang TY, Patel SA, Badar T.
europepmc   +2 more sources

Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives. [PDF]

Oncol Res
Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring KMT2A ...
Chen T, Kim G, Rahimi Y, Kamdar M, Fernandez-Hernandez E, Woan K, Tam EL, Yaghmour G.   +7 more
europepmc   +2 more sources

Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias [PDF]

Cancers
Carla Mazzone, Paolo de Fabritiis, Pasquale Niscola   +2 more
exaly   +2 more sources

Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment

Biomedicines, 2021
The tumor suppressor menin has dual functions, acting either as a tumor suppressor or as an oncogene/oncoprotein, depending on the oncological context.
Dang Tan Nguyen, Thi Khanh Le, Clément Paris, Chaïma Cherif, Stéphane Audebert, Sandra Oluchi Udu-Ituma, Sébastien Benizri, Philippe Barthélémy, François Bertucci, David Taïeb, Palma Rocchi   +10 more
doaj   +1 more source

Targeting the MLL complex in acute leukemia [PDF]

, 2014
Chromosomal rearrangements leading mostly to fusion oncoproteins of the Mixed Lineage Leukemia (MLL) gene occur in about 10% of all patients with acute leukemia and are often associated with poor clinical outcome, emphasizing the need for new treatment ...
Méreau, Hélène
core   +1 more source

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML

HemaSphere, 2023
Chromosomal translocations involving the NUP98 locus are among the most prevalent rearrangements in pediatric acute myeloid leukemia (AML). AML with NUP98 fusions is characterized by high expression of HOXA and MEIS1 genes and is associated with poor ...
Milad Rasouli, Helen Blair, Selina Troester, Katarzyna Szoltysek, Rachel Cameron, Minoo Ashtiani, Anja Krippner-Heidenreich, Florian Grebien, Gerard McGeehan, C. Michel Zwaan, Olaf Heidenreich   +10 more
doaj   +1 more source

Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancer

Cancer Cell International, 2022
Background Ovarian cancer (OC) is characterized by a low response rate and high frequency of resistance development to currently available treatments.
Elena Alexandrova, Jessica Lamberti, Domenico Memoli, Claudia Quercia, Viola Melone, Francesca Rizzo, Roberta Tarallo, Giorgio Giurato, Giovanni Nassa, Alessandro Weisz   +9 more
doaj   +1 more source

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition [PDF]

, 2023
Menin interacts with oncogenic MLL1-fusion proteins, and small molecules that disrupt these associations are in clinical trials for leukemia treatment.
Gu, Shengqing, Anand, Disha, Krivtsov, Andrei V, Armstrong, Scott A, Cheon, David, Carroll, Thomas, Liu, X Shirley, Sánchez-Rivera, Francisco J, Soto-Feliciano, Yadira M, Beytagh, Mary Clare, Meneses, Maximiliano, Perner, Florian, Xiong, Yijun, Barrows, Douglas W, de Stanchina, Elisa, Lowe, Scott W, Kastenhuber, Edward R, Ho, Yu-Jui, Soshnev, Alexey A, Allis, C David, Stone, Richard M, Gates, Leah   +21 more
core   +1 more source

Discovery of Novel, Potent, and Selective Small-Molecule Menin–Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups

, 2022
Introduction of the N,N-dimethylaminoethoxy group to pyrido[3,2-d]pyrimidine led to the discovery of menin–mixed lineage leukemia (MLL) interaction inhibitor C20. C20 showed strong binding affinity to menin protein and achieved sub-micromolar potency in
San-Qi Zhang (2688940), Hongyan Chuai (13883295), Huanrong Bai (13883292), Minhang Xin (6116405), Hong-Yi Zhao (2936910), Hao Lei (335573), Jiajia Sun (843912)   +6 more
core   +2 more sources

Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration

Cell Communication and Signaling, 2018
Background Mammalian target of rapamycin (mTOR) is a master regulator of various cellular responses by forming two functional complexes, mTORC1 and mTORC2. mTOR signaling is frequently dysregulated in pancreatic neuroendocrine tumors (PNETs).
Masoud Razmara, Azita Monazzam, Britt Skogseid   +2 more
doaj   +1 more source